Advertisement
Screener

Harrow, Inc. (HROW) Increase (Decrease) in Accounts Payable

2.8 / 5 stars · 68/120 Roast Me

Harrow, Inc. Increase (Decrease) in Accounts Payable

Harrow, Inc. (HROW) reported Increase (Decrease) in Accounts Payable of $38.10 thousand for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-10.

Discontinued › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2012-05-10

  • Harrow, Inc. increase (decrease) in accounts payable for the quarter ending 2012-03-31 was $38.10K, a 56.30% decline year-over-year.
  • Harrow, Inc. increase (decrease) in accounts payable for the quarter ending 2011-12-31 was $40.20K.
  • Harrow, Inc. increase (decrease) in accounts payable for the quarter ending 2011-09-30 was $2.35K.
  • Harrow, Inc. increase (decrease) in accounts payable for the quarter ending 2011-06-30 was $15.25K.
  • Harrow, Inc. increase (decrease) in accounts payable for fiscal 2011 was $144.98K.
  • Harrow, Inc. increase (decrease) in accounts payable for fiscal 2010 was -$607.38K.
Period endIncrease (Decrease) in Accounts Payable 3 monthIncrease (Decrease) in Accounts Payable 6 monthIncrease (Decrease) in Accounts Payable 9 monthIncrease (Decrease) in Accounts Payable 12 monthIncrease (Decrease) in Accounts Payable 155 monthIncrease (Decrease) in Accounts Payable 158 monthIncrease (Decrease) in Accounts Payable 161 monthIncrease (Decrease) in Accounts Payable 164 month
2012-03-31$38.10K
10-Q · filed 2012-05-10
$78.30K
derived: sum of 2 quarters · filed 2012-05-10
$80.65K
derived: sum of 3 quarters · filed 2012-05-10
$95.89K
derived: sum of 4 quarters · filed 2012-05-10
$346.62K
10-Q · filed 2012-05-10
2011-12-31$40.20K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
$42.55K
derived: sum of 2 quarters · filed 2012-02-23
$57.80K
derived: sum of 3 quarters · filed 2012-02-23
$144.98K
10-K · filed 2012-02-23
$308.53K
10-K · filed 2012-02-23
2011-09-30$2.35K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23
$17.59K
derived: sum of 2 quarters · filed 2012-02-23
$104.78K
10-Q · filed 2012-02-23
$76.25K
derived: sum of 4 quarters · filed 2012-05-10
$268.33K
10-Q · filed 2012-02-23
2011-06-30$15.25K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-02-23
$102.43K
10-Q · filed 2012-02-23
$73.90K
derived: sum of 3 quarters · filed 2012-05-10
$27.56K
derived: sum of 4 quarters · filed 2012-05-10
$265.98K
10-Q · filed 2012-02-23
2011-03-31$87.18K
10-Q · filed 2012-05-10
$58.66K
derived: sum of 2 quarters · filed 2012-05-10
$12.31K
derived: sum of 3 quarters · filed 2012-05-10
2010-12-31-$28.53K
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
-$74.87K
derived: sum of 2 quarters · filed 2012-02-23
-$607.38K
10-K · filed 2012-02-23
2010-09-30-$46.35K
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-02-23
-$578.86K
10-Q · filed 2012-02-23
2010-06-30-$532.51K
10-Q · filed 2012-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
Avalyn Pharma Inc. (AVLN)United States$1.267B
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Jaguar Health, Inc. (JAGX)United States$1.184B
Latigo Biotherapeutics, Inc. (LTGO)United States$1.176B
Bicara Therapeutics Inc. (BCAX)United States$1.309B-10.55
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
Kardigan, Inc. (KARD)United States$1.346B